Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888818 | 0.87 | ALDH1A1 (0.44) | TSHRALDH1A1HCAR2RAB9A | |
| SCHEMBL4886762 | 0.75 | TSHR (0.43) | TSHRHCAR2CA1CA2CA7 | |
| Iodide SCHEMBL5208788 | 0.74 | TSHR (0.42) | TSHRHCAR2CA1CA2CA7 | |
| SCHEMBL4899447 | 0.74 | TSHR (0.42) | TSHRHCAR2 | |
| SCHEMBL4887410 | 0.70 | TSHR (0.47) | TSHRTP53CA1CA2CA7 | |
| SCHEMBL15555557 | 0.70 | ALDH1A1 (0.49) | TSHRALDH1A1HCAR2SMN1; SMN2RAB9A | |
| Propane SCHEMBL11584021 | 0.69 | TSHR (0.83) | TSHRALDH1A1TP53CA1CA2 | |
| SCHEMBL13638355 | 0.68 | TSHR (0.54) | TSHRALDH1A1CA1CA2CA7 | |
| SCHEMBL3028010 | 0.68 | TSHR (0.44) | TSHRALDH1A1TP53SMN1; SMN2RAB9A | |
| SCHEMBL5311581 | 0.66 | TSHR (1.00) | TSHRALDH1A1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | PFIZER INC | 2008-07-24 | — | — | US | disclosed |
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | PFIZER INC | 2008-07-24 | — | — | US | disclosed |
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | PFIZER INC | 2008-07-24 | — | — | US | disclosed |
| US-20080132549-A1 | Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids | PFIZER INC. (US) | 2008-06-05 | — | — | US | disclosed |
| EP-1838679-A1 | IMIDAZOLE DERIVATIVES AS ENZYME REVERSE TRANSCRIPTASE MODULATORS | Pfizer Limited (GB) | 2007-10-03 | — | — | EP | disclosed |
| EP-1740550-A1 | SULPHUR-LINKED IMIDAZOLE COMPOUNDS FOR THE TREAMENT OF HIV | Pfizer Limited (GB) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006072833-A1 | IMIDAZOLE DERIVATIVES AS ENZYME REVERSE TRANSCRIPTASE MODULATORS | PFIZER LIMITED (GB) | 2006-07-13 | — | — | WO | disclosed |
| WO-2005100322-A1 | SULPHUR-LINKED IMIDAZOLE COMPOUNDS FOR THE TREAMENT OF HIV | PFIZER LIMITED (GB) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132549-A1 | Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids | SPR, TPMT, IMPDH1 | TSHR 3874/4885ALDH1A1 84/4885HCAR2 3972/4885 |
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | POLRMT, POLR1G, POLR2A | TSHR 1981/4885ALDH1A1 216/4885HCAR2 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.